26
|
Giunta E, De Falco V, Napolitano S, Vitale P, Zanaletti N, Terminiello M, Caputo V, Vitiello P, Ciardiello D, Borrelli C, Poliero L, Arrichiello G, Cardone C, Martini G, Martinelli E, Ciardiello F, Troiani T. P-200 Bone metastases from colorectal cancer correlate with biological characteristics of primary tumors: A retrospective analysis from a single institution. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
27
|
Napolitano S, Matrone N, Muddassir AL, Martini G, Sorokin A, De Falco V, Giunta EF, Ciardiello D, Martinelli E, Belli V, Furia M, Kopetz S, Morgillo F, Ciardiello F, Troiani T. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2019; 38:492. [PMID: 31842958 PMCID: PMC6915948 DOI: 10.1186/s13046-019-1497-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 11/29/2019] [Indexed: 02/06/2023]
Abstract
BACKGROUND Molecular mechanisms driving acquired resistance to anti-EGFR therapies in metastatic colorectal cancer (mCRC) are complex but generally involve the activation of the downstream RAS-RAF-MEK-MAPK pathway. Nevertheless, even if inhibition of EGFR and MEK could be a strategy for overcoming anti-EGFR resistance, its use is limited by the development of MEK inhibitor (MEKi) resistance. METHODS We have generated in vitro and in vivo different CRC models in order to underline the mechanisms of MEKi resistance. RESULTS The three different in vitro MEKi resistant models, two generated by human CRC cells quadruple wild type for KRAS, NRAS, BRAF, PI3KCA genes (SW48-MR and LIM1215-MR) and one by human CRC cells harboring KRAS mutation (HCT116-MR) showed features related to the gene signature of colorectal cancer CMS4 with up-regulation of immune pathway as confirmed by microarray and western blot analysis. In particular, the MEKi phenotype was associated with the loss of epithelial features and acquisition of mesenchymal markers and morphology. The change in morphology was accompanied by up-regulation of PD-L1 expression and activation of EGFR and its downstream pathway, independently to RAS mutation status. To extend these in vitro findings, we have obtained mouse colon cancer MC38- and CT26-MEKi resistant syngeneic models (MC38-MR and CT26-MR). Combined treatment with MEKi, EGFR inhibitor (EGFRi) and PD-L1 inhibitor (PD-L1i) resulted in a marked inhibition of tumor growth in both models. CONCLUSIONS These results suggest a strategy to potentially improve the efficacy of MEK inhibition by co-treatment with EGFR and PD-L1 inhibitors via modulation of host immune responses.
Collapse
|
28
|
Ciardiello D, Belli V, Cardone C, Vitiello P, Martini G, Poliero L, Borrelli C, Arrichiello G, Ciaramella V, Matrone N, Barra G, De Falco V, Giunta E, Morgillo F, Troiani T, Terminiello M, Melisi D, Ciardiello F, Martinelli E. Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz238.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Martini G, Elez E, Mancuso F, España MAG, Caratù G, Matito J, Martinez GA, Margalef NM, Morales MJO, Montana FJR, Garcia A, Comas R, Vivas CS, Perez-Lopez R, Nuciforo P, Casanovas O, Dienstmann R, Tabernero J, Aguilar EA, Vivancos A. RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Vitiello P, Ciardiello D, Cardone C, Martini G, Belli V, Borrelli C, Poliero L, Arrichiello G, De Falco V, Giunta E, Terminiello M, Troiani T, Ciardiello F, Martinelli E. Synergistic activity between niraparib and chemotherapy in colorectal cancer: Molecular determinants from a preclinical model. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz238.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Cardone C, Blauensteiner B, Moreno-Viedma V, Vitiello P, Martini G, Ciardiello D, Simeon V, Rachiglio A, Rizzi D, Maiello E, Latiano T, Cremolini C, Argiles Martinez G, Elez E, Falcone A, Tabernero J, Normanno N, Sibilia M, Ciardiello F, Martinelli E. AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
32
|
Vitale P, Zanaletti N, Vitiello P, martinelli E, Ciardiello D, De Falco V, Giunta E, Poliero L, Terminiello M, Borrelli C, Caputo V, Arrichiello G, Martini G, Stefania N, Famiglietti V, Cardone C, Ciardiello F, Troiani T. Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Cardone C, Blauensteiner B, Moreno-Viedma V, Paul M, Martini G, Troiani T, Vitiello P, Ciardiello D, Poliero L, Borrelli C, Rachiglio A, Rizzi D, Maiello E, Latiano T, Normanno N, Sibilia M, Ciardiello F, Martinelli E. Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz156.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Ciardiello D, Martini G, Matrone N, Belli V, Vitiello P, Cardone C, Ciaramella V, Barra G, Poliero L, Borrelli C, Troiani T, Melisi D, Morgillo F, Giunta E, De Falco V, Ciardiello F, Martinelli E. Functional inhibition of TGF-β in colorectal cancer cells and its interaction with AXL receptor. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy268.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Vitiello P, Cardone C, Ciardiello D, Barra G, Matrone N, Belli V, Martini G, Poliero L, Borrelli C, Terminiello M, Troiani T, Morgillo F, Ciardiello F, Martinelli E. Receptor tyrosine kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy268.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Cardone C, Blauensteiner B, Moreno-Viedma V, Paul M, Martini G, Vitiello P, Ciardiello D, Borrelli C, Poliero L, Vitale P, Zanaletti N, Famiglietti V, Rachiglio A, Rizzi D, Maiello E, Latiano T, Normanno N, Sibilia M, Ciardiello F, Martinelli E. AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Mulet N, Matos I, Noguerido A, Martini G, Élez ME, Argilés G, Tabernero J. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer. Expert Opin Pharmacother 2018. [DOI: 10.1080/14656566.2018.1453497] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
38
|
Comacchio F, Ricca M, Martini G, Cecchin V, Zannin ME. Ocular nonsuicidal self-injury in a teenager. Oman J Ophthalmol 2018; 11:55-57. [PMID: 29563698 PMCID: PMC5848351 DOI: 10.4103/ojo.ojo_209_2016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
A 14-year-old male teen presented with unilateral episcleritis, unresponsive to topical and systemic corticosteroid therapy, without a history of ocular trauma or evidence for systemic diseases. The presence of foreign bodies in the conjunctival mucus of the hyperemic fornix has been noticed during one of the follow-up examinations. The toxicological analysis of conjunctival mucus revealed the presence of ethylene glycolmonomethyl ether and triethilene glicolebuthyl ether, used as solvents in nail polish removers and all-purpose cleaners. An unexpected etiology of chemical self-inflicted episcleritis was determined. The teen was admitted to a psychological assessment, after which a psychotherapeutic treatment was recommended. Episcleritis is characterized by the acute onset of ocular pain and redness, with a frequent recurrent and stressful course. Since it can be associated with life-threatening systemic vasculitides, a prompt, aggressive immunosuppressive therapy may be considered, both for the ocular inflammation and for the underlying systemic condition. Rarely episcleritis does not improve despite topical and systemic therapy, administered in a stepladder way. The reported teenager case needed a complex multidisciplinary approach to achieve the correct diagnosis and to avoid unnecessary treatments. In the case of recognized “nonsuicidal self-injury,” a psychological evaluation is strongly recommended, to identify and address underlying neuropsychiatric problems.
Collapse
|
39
|
Di Giovanni C, Puggina S, Meneghel A, Vittadello F, Martini G, Zulian F. Cone beam computed tomography for the assessment of linear scleroderma of the face. Pediatr Rheumatol Online J 2018; 16:1. [PMID: 29298697 PMCID: PMC5751836 DOI: 10.1186/s12969-017-0218-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Accepted: 12/21/2017] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND To date, standardized methods for assessing the disease progression of linear scleroderma of the face (LSF) are lacking. OBJECTIVES We investigated whether Cone Beam Computed Tomography (CBCT) may represent a reliable tool for assessing linear scleroderma of the face (LSF). METHODS Ten patients with LSF and five age-matched controls underwent CBCT assessment. The transverse sections at three anatomic levels of the maxillofacial bones were analyzed. Measurements of soft tissue and total thickness of both affected and unaffected side of the face were made by a standardized methodology. Six raters evaluated CBCTs twice and blindly one from the other. The intra- and inter-rater reliability was assessed by the Intraclass Correlation Coefficient (ICC). RESULTS CBCT was fast and well tolerated by the patients. The inter-rater concordance for the total thickness was excellent, mean ICC 0.75 for patients, 0.89 for controls. The mean ICC for soft tissue thickness was 0.49 for patients, 0.66 for controls. 58.3% of the measurements for patients and 91.2% of those for controls showed excellent ICC results (≥ 0.75). The intra-rater concordance resulted optimal (ICC 0.77-0.99). CONCLUSIONS CBCT is a reliable technique to assess skin and bony changes of LSF.
Collapse
|
40
|
Martini G, Belli V, Vitiello P, Troiani T, Cardone C, Napolitano S, Matrone N, Sforza V, Savastano B, Renato F, Morgillo F, Della Corte C, Ciardiello D, Giunta E, De Falco V, Zanaletti N, Vitale P, Ciardiello F, Martinelli E. EPHA2 receptor is involved in in vivo acquired resistance to anti-epidermal growth factor receptor (EGFR) treatment in metastatic colorectal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Cardone C, Paul M, Moreno-Viedma V, Martini G, Vitiello P, Ciardiello D, Sforza V, Troiani T, Napolitano S, Vitale P, Zanaletti N, Rachiglio A, Rizzi D, Maiello E, Normanno N, Sibilia M, Ciardiello F, Martinelli E. Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Vitiello P, Viscardi G, Martini G, Cardone C, Ciardiello D, Belli V, Matrone N, Troiani T, Napolitano S, Sforza V, De Falco V, Giunta E, Morgillo F, Diadema M, Vitale P, Zanaletti N, Ciardiello F, Martinelli E. The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Martini G, Belli V, Vitiello P, Troiani T, Cardone C, Napolitano S, Matrone N, Sforza V, Franco R, Morgillo F, Ciardiello D, Giunta E, De Falco V, Zanaletti N, Vitale P, Martinelli E, Ciardiello F. EPHA2 receptor is involved in in vivo acquired resistance to anti-Epidermal Growth Factor Receptor (EGFR) treatment in metastatic colorectal cancer (mCRC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Cardone C, Paul M, Moreno-Viedma V, Martini G, Vitiello P, Ciardiello D, Sforza V, Troiani T, Napolitano S, Vitale P, Zanaletti N, Rachiglio A, Rizzi D, Maiello E, Normanno N, Sibilia M, Ciardiello F, Martinelli E. Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Napolitano S, Martini G, Martinelli E, Della Corte C, Belli V, Matrone N, Morgillo F, Ciardiello F, Troiani T. Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM-151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Vitiello P, Martini G, Cardone C, Ciardiello D, Belli V, Matrone N, Troiani T, Napolitano S, Sforza V, Papaccio G, Desiderio V, De Falco V, Giunta E, Morgillo F, Diadema M, Vitale P, Zanaletti N, Ciardiello F, Martinelli E. The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx361.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Martini G, Bobbi S, Marconi G, Morini R, Albanese B, Pasquini G, Manescalchi P, Bartoli V. Studies of erythrocyte membranes by ESR of spin probe. Clin Hemorheol Microcirc 2016. [DOI: 10.3233/ch-1984-42-321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
48
|
Napolitano S, Belli V, Castellone M, Parascandolo A, Martinelli E, Martini G, Cardone C, Morgillo F, Orditura M, Ciardiello F, Troiani T. SYM004, a novel generation anti-EGFR inhibitor, is able to overcome acquired resistance to cetuximab such as MET activation, ERBB2 amplification and EGFR mutations, in colorectal cancer models. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw362.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Martini G, Belli V, Vitiello P, Troiani T, Cardone C, Napolitano S, Sforza V, Ferrara M, Morgillo F, Ciardiello D, Giunta E, Ciardiello F, Martinelli E. AXL activation can promote resistance to MEK inhibition in a model of colorectal cancer (CRC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw362.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
50
|
Franzese E, Martini G, Cardone C, Troiani T, Sforza V, Ferrara M, Belli V, Vitiello P, Napolitano S, Zanaletti N, Vitale P, De Vita F, Orditura M, Morgillo F, Ciardiello F, Martinelli E. Transforming growth factor beta receptor (TGF&bgr;R) pathway is involved in ligand independent transactivation of AXL receptor in colorectal cancer (CRC) cell lines. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw362.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|